Docusate
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Docusate: Plummer-Vinson syndrome
One-Sentence Summary
Docusate is a surfactant stool softener used for constipation. Any scores on this page come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The TxGNN model predicts it may be effective for Plummer-Vinson syndrome, but there are currently 0 clinical trials and 0 publications supporting this direction. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Plummer-Vinson syndrome |
| TxGNN Prediction Score | 0.9918 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Docusate is an anionic surfactant stool softener, and its efficacy in constipation is established. There is no known mechanism linking it to Plummer-Vinson syndrome.
Plummer-Vinson syndrome is characterised by iron deficiency anaemia together with oesophageal webs. The high score (0.9918) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Docusate has no known effect on iron absorption or on oesophageal webs, so the link has no pharmacological rationale.
Other top-ranked predictions show the same pattern. They include B12- and folate-independent megaloblastic anaemia (0.9915), which sits close to the anaemia indications. None has any trial or publication support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 4199B | Waxsol | Ear drops 5 mg per mL (0.5%), 10 mL | Not recorded in the data compiled for this report |
Note that the only ARTG entry is an ear-drop product (ceruminolytic use). It is not an oral laxative formulation, so no registered route matches the predicted systemic indications.
Safety Considerations
- Drug Interactions (4 recorded):
- Lactulose: Moderate
- Mineral oil: Moderate
- Phenolphthalein: Moderate
- Linaclotide: Minor
- Disease-level contraindication signals (from the knowledge graph, not product label text): peptic ulcer disease, potassium deficiency, sickle cell anaemia, haemolytic anaemia, hereditary haemochromatosis, haemosiderosis, iron metabolism disease, Wilson disease, ulcerative colitis, inflammatory bowel disease, appendicitis, chronic atrophic gastritis, gastroenteritis, primary hyperoxaluria, hereditary persistence of fetal haemoglobin and Leber hereditary optic neuropathy.
Warnings and contraindications from the TGA-approved Product Information (PI) were not available. Please refer to the PI for confirmed safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5), with no trials, no literature and no plausible mechanism. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
To proceed, the following is needed:
- Mechanism of action data for docusate, and a testable hypothesis for Plummer-Vinson syndrome
- Product Information warnings and contraindications for a relevant formulation
- Any preclinical or clinical evidence supporting benefit in the predicted condition
- A route and formulation assessment, since the only ARTG entry is an ear-drop product
- Consideration of whether a more established treatment, such as iron replacement and oesophageal dilatation for Plummer-Vinson syndrome, already addresses the need
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.